Personalized B-cell tailored dosing of ocrelizumab in patients with multiple sclerosis during the COVID-19 pandemic.

Zoë Y. Gj van Lierop,Alyssa A. Toorop,Wouter J. C. van Ballegoij,Tom B. G. Olde Dubbelink,Eva M. M. Strijbis,Brigit A. de Jong,Bob W. van Oosten,B. Moraal,Charlotte E. Teunissen,Bernard M. J. Uitdehaag,Joep Killestein,Zoé L. E. van Kempen

Personalized B-cell tailored dosing of ocrelizumab in patients with multiple sclerosis during the COVID-19 pandemic.

2021

Zoë Y. Gj van Lierop
Alyssa A. Toorop
Wouter J. C. van Ballegoij
Tom B. G. Olde Dubbelink
Eva M. M. Strijbis
Brigit A. de Jong
Bob W. van Oosten
B. Moraal
Charlotte E. Teunissen
Bernard M. J. Uitdehaag
Joep Killestein
Zoé L. E. van Kempen

In this observational study, 159 patients with multiple sclerosis received personalized dosing of ocrelizumab incentivized by the COVID-19 pandemic. Re-dosing was scheduled when CD19 B-cell count w...

Keywords:

Pandemic
Ocrelizumab
Coronavirus disease 2019
Observational study
Dosing
Internal medicine
Multiple sclerosis
in patient
B cell
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations